Discovery of Therapeutic sdAb Against COVID-19
Creative Biolabs is always dedicated to assisting our clients with the most satisfactory sdAb-based drug discovery. In response to the increasingly severe COVID-19 infection situation, we are pleased to contribute our extensive experience in sdAb discovery and development to help our customers generating high-quality therapeutic sdAb against COVID-19.
Introduction of COVID-19
COVID-19 is a newly identified coronavirus belongs to the family Coronaviridae. It is a positive-sense single-stranded RNA virus in a variety of animals and also can infect humans. In recent years, the SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), and now COVID-19 infections are lethal endemics which have been spreading in multiple countries. To deal with the current severe epidemic situation, Creative Biolabs can offer a series of one-stop solutions to develop novel sdAbs as therapeutic reagents to meet your specific project demands.
Potential Targets from SARS-CoV-2
Belonging to the Betacoronavirus genus, the SARS-CoV-2 has a genome size of ~30 kilobases to encode multiple structural and non-structural proteins. The full-length genome phylogenetic analysis showed that SARS-CoV-2 is close to SARS-CoV much more so than MERS-CoV. Compared with SARS-CoV, SARS-CoV-2 presents high genetic similarity for structural proteins, including the spike (S) protein (76%), the envelope (E) protein (94.7%), the membrane (M) protein (90.1%), and the nucleocapsid (N) protein (90.6%). In this case, the immunological studies of SARS-CoV have a guiding significance to the research on SARS-CoV-2. S protein and N protein are always hot targets as they can induce potent and long-lived immune responses. The in-depth study of epitopes in the S and N proteins can potentially narrow the search for potent targets and further vaccine development against SARS-CoV-2.
Fig.1 Comparison of the similarity of structural proteins of SARS-CoV-2 with the corresponding proteins of SARS-CoV and MERS-CoV.1
Therapeutic sdAb Discovery Against SARS-CoV-2
Single domain antibodies (sdAbs) are heavy-chain antibody fragments derived from Camelidae family of mammals and sharks. Compared with conventional antibody, sdAbs present great advantages and potentials in diagnostic and therapeutic applications, such as small size, high stability, great solubility, and high expression. In addition, the special characteristics of sdAb make it suitable for inhalation and oral administration. For therapeutic sdAb discovery and development, our scientists can work closely with you and customize the best-fit project scheme to achieve your purpose. Creative Biolabs has the full capacity to serve you from early-stage antigen preparation until the preclinical animal tests. Some of our one-stop solutions could also play a key role to assist the development of novel sdAb against COVID-19, including but not limited to:
- One-Stop Solution for sdAb Development
- One-Stop Solution for Anti-Membrane Protein sdAb Development
- One-Stop Solution for Bispecific sdAb Development
- One-Stop Solution for Anti-Idiotypic sdAb Development
As a forward-looking custom service provider in drug discovery, Creative Biolabs has won a good reputation among our worldwide customers for accomplishing numerous challenging projects. We are willing to provide a series of pharmaceutical-related services to promote your project, especially therapeutic antibody discovery. If you are interested in our services, please do not hesitate to contact us for more information.
Reference
- Ahmed, Syed Faraz, Ahmed A. Quadeer, and Matthew R. McKay. "Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies." Viruses 12.3 (2020): 254. Distributed under Open Access license CC BY 4.0, without modification.
Case Study
We are offering highly customized CRO services to assist your Single Domain Antibody (sdAb) related projects. Please Contact Us for more details.
Applications
